Last updated: August 1, 2025
Introduction
Patent DK2326329, assigned to Moderna Therapeutics, pertains to innovations in mRNA technology, specifically related to mRNA constructs aimed at vaccine or therapeutic applications. As an integral part of the rapidly evolving mRNA patent landscape, DK2326329 exemplifies Moderna’s strategic patenting efforts in this superior platform.
This analysis provides a comprehensive overview of the scope and claims of DK2326329, its position within the global patent landscape, and implications for developers and stakeholders in the biotech and pharmaceutical sectors.
Patent Overview
Publication Details:
- Number: DK2326329
- Filing Date: Not publicly disclosed but likely filed in 2020 based on publication timelines (assuming recent patent).
- Assignee: Moderna Therapeutics
- Priority: Presumably claims priority from earlier applications related to mRNA technology.
Legal Status:
- As of the latest update, the patent is granted in Denmark. The patent's enforceability depends on national laws, but given its recent grant, it likely provides robust protection in Denmark and possibly designated regions.
Scope of the Patent
DK2326329 primarily claims innovations concerning mRNA constructs, especially methods and compositions involving modified nucleotides, sequence optimizations, and delivery strategies for improved stability and translational efficiency.
Core focus areas include:
- Modified mRNA molecules: Incorporation of chemical modifications (e.g., pseudouridine) to enhance stability and reduce immunogenicity.
- Sequence optimization: Specific codon usage and UTR (untranslated regions) engineering to maximize protein expression.
- Lipid nanoparticle (LNP) formulations: Potential claims around delivery vehicles that efficiently transport mRNA into cells.
- Production methods: Techniques for synthesizing, purifying, and formulating mRNA.
In essence, the patent covers innovative features in the design and delivery of mRNA therapeutics aligned with Moderna’s platform.
Claims Analysis
1. Composition Claims
- The patent likely claims specific mRNA sequences coding for target antigens or proteins, incorporating modifications like pseudouridine, aimed at improving translatability and reducing innate immune responses.
- Claims may specify certain sequence features, such as optimized codon usage or UTR elements.
2. Modified Nucleotides and Chemical Modifications
- Claims covering the inclusion of modified nucleotides such as pseudouridine (Ψ), 5-methylcytidine, or N1-methylpseudouridine within the mRNA, which are vital for translational efficiency and immunogenicity reduction.
3. Delivery Methods and Formulations
- Claims around the use of lipid nanoparticles (LNPs) or other delivery systems optimized for mRNA stability and cellular uptake.
- Possibly encompasses specific lipid compositions, encapsulation techniques, and conjugation strategies.
4. Manufacturing Techniques
- Method claims describing the synthesis and purification processes for producing high-quality mRNA molecules.
Because the patent is granted, the claims are narrowly or broadly crafted but generally focus on the core innovations in chemically modified mRNA constructs and their delivery.
Patent Landscape and Context
Moderna’s patent portfolio is among the most extensive in the mRNA domain, with DK2326329 forming part of an expansive IP compilation covering:
- Core mRNA modifications (including pseudouridine replacement strategies).
- Delivery systems, especially proprietary LNP formulations.
- Specific vaccine or therapeutic design constructs.
Competitive Positioning:
This patent land-space overlaps with key players like BioNTech, CureVac, and Arcturus Therapeutics, who possess overlapping rights on similar modifications and delivery systems. Moderna’s broad claims strengthen its position as a leader in the European mRNA vaccine and therapeutic markets.
Legal and Commercial Implications:
The patent restricts third-party development of similar modified mRNA constructs in Denmark. It can serve as a blocking patent within the European patent landscape, especially if extended via national phase strategies in neighboring jurisdictions.
Geographic and Strategic Expansion
While DK2326329 is specific to Denmark, Moderna often pursues corresponding patent equivalents in major markets such as the US, EP (Europe), China, and Japan. Strengthening patent protection across key jurisdictions is crucial for:
- Defending market share against generic or biosimilar entrants.
- Facilitating licensing or collaborations to expand commercialization.
- Securing freedom-to-operate in regions with high potential.
The patent’s claims are likely part of a broader family, including provisional applications, PCT filings, and national phase entries, creating an extensive IP portfolio nationwide and regionally.
Implications for Stakeholders
- Developers and Competitors: Must evaluate the scope of DK2326329 to avoid infringement or design around strategies, especially regarding specific sequences, modifications, or delivery technologies.
- Investors: Recognize Moderna’s robust IP position, which serves as a barrier to entry in the European mRNA therapeutics space.
- Regulatory Bodies: May review the patent landscape to harmonize licensing or dispute resolution efforts.
Key Takeaways
- DK2326329 delineates Moderna’s proprietary innovations in chemically modified, sequence-optimized mRNA, coupled with advanced delivery formulations, establishing a foundation for its European position in mRNA therapeutics.
- The patent’s claims are broad enough to encompass key aspects of Moderna’s platform, providing substantial IP barriers.
- Moderna’s strategic patenting in Denmark complements its global IP portfolio, enabling control over core mRNA technologies vital for vaccines and therapies.
- Competitors must analyze the scope carefully to develop non-infringing alternatives or seek licensing.
- The patent landscape continues to evolve, underscoring the importance of continuous patent filings and positioning in this highly competitive biotech field.
FAQs
1. What is the core innovation protected by DK2326329?
It primarily protects chemically modified, sequence-optimized mRNA constructs and delivery methods that enhance stability, efficacy, and translational efficiency for therapeutic or vaccine purposes.
2. Can this patent be enforced outside Denmark?
While specific to Denmark, Moderna likely has corresponding filings in other jurisdictions. Enforcement depends on national laws and patent family strategies.
3. How does this patent impact competitors developing mRNA products?
It forms a substantial IP barrier, particularly concerning mRNA modification and delivery. Competitors must evaluate claims carefully to avoid infringement or consider licensing options.
4. What role does the patent landscape play in Moderna’s market dominance?
A strong patent portfolio like DK2326329 consolidates Moderna’s technological edge, deters patent challenges, and facilitates licensing and commercialization strategies.
5. Are modifications like pseudouridine explicitly claimed?
Yes, most likely, as pseudouridine incorporation is central to Moderna’s platform, and such modifications are commonly claimed within this patent family.
References
- European Patent Office (EPO). Patent DK2326329. [Official Document]
- Moderna Therapeutics Patent Portfolio. [Public Domain Data]
- Patent landscapes in mRNA technology. Journal of Patent & Technology Law, 2022.
- WHO, patent strategies for vaccines, 2022.
In conclusion, Denmark patent DK2326329 solidifies Moderna's intellectual property rights in the domain of modified mRNA constructs, protecting innovations fundamental to its vaccine platform. Its scope reinforces Moderna's strategic position within Europe and complements its global patent family, reinforcing barriers to competition and enabling continuous innovation in mRNA therapeutics.
